Shop



Orbax Oral Suspension is a new liquid formulation of orbifloxacin features ion-exchange taste-masking technology that allows the medication to pass the tastebuds undetected to ensure easy administration. Approved for use in both dogs and cats for the management of diseases associated with bacteria susceptible to orbifloxacin.
Add this item to your cart:

Item# Size/Desc Qty Price
161654
30mg/mL 20mL
$45.99
$31.99
Save $14.00!  
This item requires a RX

**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.



DOSAGE AND ADMINISTRATION:

Shake Well Before Use.
BEFORE INITIAL USE, remove the cap and insert the syringe adaptor by pressing firmly into top of bottle. Insert the syringe tip into the adaptor opening and invert the bottle.
Withdraw the required amount of medication with the calibrated syringe.
After use, replace cap, leaving adaptor in the bottle, and rinse the syringe with water.
The dose of ORBAX® Oral Suspension in the dog is 1.1 to 3.4 mg/lb 2.5 to 7.5 mg/kg of body weight administered once daily .
The determination of dosage for any particular patient must take into consideration such factors as the severity and nature of the infection, the susceptibility of the causative organism, and the integrity of the patient&rsquos host-defense mechanisms. Antibiotic susceptibility of the pathogenic organisms should be determined prior to use of this preparation. Therapy with ORBAX® Oral Suspension may be initiated before results of these tests are known. Once results become available, continue with appropriate therapy. For the treatment of skin infections, ORBAX® Oral Suspension should be given for two 2 to three 3 days beyond the cessation of clinical signs to a maximum of 30 days. For the treatment of urinary tract infections, ORBAX® Oral Suspension should be administered for at least 10 consecutive days. If no improvement is seen within five 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

CONTRAINDICATIONS:

Orbifloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. Orbifloxacin is contraindicated in immature dogs during the rapid growth phase between 2 and 8 months of age in small and medium-sized breeds, and up to 18 months of age in large and giant breeds. Orbifloxacin is contraindicated in dogs known to be hypersensitive to quinolones. HUMAN

WARNING:

For use in animals only. Keep out of the reach of children. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposure.

PRECAUTIONS:

Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens. Administer orbifloxacin with caution in the presence of hepatic insufficiency/impairment. Please refer to the cat side of this package insert for Precautions related specifically to cats. Quinolones should be used with caution in animals with known or suspected central nervous system CNS disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation, which may lead to convulsive seizures. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. The safety of orbifloxacin in animals that are used for breeding or that are pregnant and/or lactating has not been demonstrated.

DRUG INTERACTIONS:

Compounds eg, sucralfate, antacids, and multivitamins containing divalent and trivalent cations eg, iron, aluminum, calcium, magnesium, and zinc may substantially interfere with the absorption of quinolones resulting in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided. The dosage of theophylline should be reduced when used concurrently with fluoroquinolones. Cimetidine has been shown to interfere with the metabolism of fluoroquinolones and should be used with care when used concurrently. Concurrent use of fluoroquinolones with oral cyclosporine is contraindicated. Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.

ADVERSE REACTIONS:

In a field study, when the tablet formulation of orbifloxacin was administered at 2.5 mg/kg/day, no drug-related adverse reactions were reported. In a foreign field study using the oral suspension at 7.5 mg/kg/day, vomiting was reported for ORBAX® Oral Suspension and the comparator. Post Approval Experience with ORBAX® orbifloxacin Tablets Rev. 2010: The following adverse events are based on post-approval adverse drug experience reporting with ORBAX® orbifloxacin Tablets. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reporting frequency: DOG: Vomiting, convulsions, depression/lethargy, anorexia For a complete listing of adverse reactions for ORBAX® orbifloxacin Tablets reported to the CVM see: http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/ucm055394.htm For technical assistance or to report a suspected adverse reaction call 1-800-224-5318.


DRUG INTERACTIONS:

Compounds eg, sucralfate, antacids, and multivitamins containing divalent and trivalent cations eg, iron, aluminum, calcium, magnesium, and zinc may substantially interfere with the absorption of quinolones resulting in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided. The dosage of theophylline should be reduced when used concurrently with fluoroquinolones. Cimetidine has been shown to interfere with the metabolism of fluoroquinolones and should be used with care when used concurrently. Concurrent use of fluoroquinolones with oral cyclosporine is contraindicated. Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.

ADVERSE REACTIONS:

In a field study, when the tablet formulation of orbifloxacin was administered at 2.5 mg/kg/day, no drug-related adverse reactions were reported. In a foreign field study using the oral suspension at 7.5 mg/kg/day, vomiting was reported for ORBAX® Oral Suspension and the comparator. Post Approval Experience with ORBAX® orbifloxacin Tablets Rev. 2010: The following adverse events are based on post-approval adverse drug experience reporting with ORBAX® Tablets. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reporting frequency: CAT: Blindness, mydriasis, anorexia, ataxia, depression/lethargy, vomiting, convulsions, abnormal retina, hypersalivation. In some cases, blindness has been temporary.